IMA901: A multi-peptide cancer vaccine for treatment of renal cell cancer

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 11, 2014, Pages 3179-3189

  Kirner, Alexandra ^a   Mayer Mokler, Andrea ^a   Reinhardt, Carsten ^a  

^a IMMATICS BIOTECHNOLOGIES GMBH   (Germany)

Author keywords

Cancer vaccine; Checkpoint inhibitor; Cyclophosphamide; GM CSF; IMA901; Immunotherapy; Kidney cancer; Renal cell carcinoma; Tumor associated peptides; Vaccination

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BMS 936559; CANCER VACCINE; CYCLOPHOSPHAMIDE; CYTOKINE; DURVALUMAB; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMA 901; INTERLEUKIN 2; MAG 271; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MPDL 3280A; NIVOLUMAB; PAZOPANIB; PEMBROLIZUMAB; PEPTIDE; PEPTIDE VACCINE; PHOSPHOTRANSFERASE INHIBITOR; PIDILIZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; SIPULEUCEL T; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TUMOR ASSOCIATED PEPTIDE; UNCLASSIFIED DRUG; IMA901 VACCINE; SUBUNIT VACCINE;

ADVANCED CANCER; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELLULAR IMMUNITY; COUGHING; DRUG MEGADOSE; DRUG RESPONSE; DYSPNEA; FATIGUE; FEVER; HEADACHE; HUMAN; INFLUENZA; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHADENITIS; NONHUMAN; T LYMPHOCYTE; TUMOR CELL; CARCINOMA, RENAL CELL; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; PROCEDURES; VACCINATION;

CANCER VACCINES; CARCINOMA, RENAL CELL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; T-LYMPHOCYTES; VACCINATION; VACCINES, SUBUNIT;

EID: 84921818011     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/21645515.2014.983857     Document Type: Article

References (82)

1. Lynch CF, Cohen MB. Urinary system. Cancer 1995;75(1 Suppl):316-29; PMID:8001003; http://dx.doi.org/10.1002/1097-0142(19950101)75:1C%3c316::AID-CNCR2820751314%3e3.0.CO;2-T
2. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001;166(5):1611-23; PMID:11586189; http://dx.doi.org/10.1016/S0022-5347(05)65640-6
3. Chow WH, Devesa SS, Warren JL, Fraumeni JF, Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999;281(17):1628-31; PMID:10235157; http://dx.doi.org/10.1001/jama.281.17.1628
4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108; PMID:15761078; http://dx.doi.org/10.3322/canjclin.55.2.74
5. Murai M, Oya M. Renal cell carcinoma: etiology, incidence and epidemiology. Curr Opin Urol 2004;14 (4):229-33; PMID:15205579; http://dx.doi.org/10.1097/01.mou.0000135078.04721.f5
6. Marugame T, Matsuda T. Comparison of time trends in kidney cancer incidence (1973-97) in East Asia, Europe and USA, from cancer incidence in five continents, Vols IV-VIII. Jpn J Clin Oncol 2008;38 (7):508-9; PMID:18664483; http://dx.doi.org/10.1093/jjco/hyn060
7. Vaishampayan UN, Do H, Hussain M, Schwartz K. Racial disparity in incidence patterns and outcome of kidney cancer. Urology 2003;62(6):1012-7; PMID:14665346; http://dx.doi.org/10.1016/j.urology.2003.07.010
8. Horner MJ, Ries LAG, Krapcho M et al. SEER Cancer Statistics Review, 1975-2006. based on November 2008 SEER data submission. 2009. http://seer.cancer. gov/csr/1975-2006/, National Cancer Institute. Bethesda, MD.
9. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol 2006;176(6 Pt 1):2353-8; PMID:17085101; http://dx.doi.org/10.1016/j.juro.2006.07.130
10. Pascual D, Borque A. Epidemiology of kidney cancer. Adv Urol 2008;782381; PMID:19009036
11. Nepple KG, Yang L, Grubb RL, III, Strope SA. Population based analysis of the increasing incidence of kidney cancer in the United States: evaluation of age specific trends from 1975 to 2006. J Urol 2012;187 (1):32-38; PMID:22088338; http://dx.doi.org/10.1016/j.juro.2011.09.028
12. Nepple, Wood. Kidney cancer on the rise. 2011. Genitourinary Cancers Symposium, Orlando, Fla., Feb. Seventeen-19, 2011.
13. Levi F, Ferlay J, Galeone C, Lucchini F, Negri E, Boyle P, La Vecchia C. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int 2008;101(8):949-58; PMID:18241251; http://dx.doi. org/10.1111/j.1464-410X.2008.07451.x
14. Mathew A, Devesa SS, Fraumeni JF, Jr., Chow WH. Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev 2002;11(2): 171-8; PMID:11984136; http://dx.doi.org/10.1097/00008469-200204000-00010
15. Tate R, Iddenden R, Harnden P et al. Increased incidence of renal parenchymal carcinoma in the Northern and Yorkshire region of England, 1978-1997. Eur J Cancer 2003;39(7):961-7; PMID:12706365; http:// dx.doi.org/10.1016/S0959-8049(03)00070-4
16. Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J 2008;14(5):288-301; PMID:18836333; http://dx.doi.org/10.1097/PPO.0b013e3181867628
17. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014.CA Cancer J Clin 2014;64(1):9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
18. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008.Eur J Cancer 2010;46(4):765-781; PMID:20116997; http://dx.doi.org/10.1016/j.ejca.2009.12.014
19. Prasad SR, Humphrey PA, Catena JR, Narra VR, Srigley JR, Cortez AD, Dalrymple NC, Chintapalli KN. Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. Radiographics 2006;26(6):1795-1806; PMID:17102051; http://dx.doi.org/10.1148/ rg.266065010
20. Cheng L, Zhang S, MacLennan GT, Lopez-Beltran A, Montironi R. Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol 2009;40(1):10-29; PMID:19027455; http://dx. doi.org/10.1016/j.humpath.2008.09.009
21. Algaba F, Trias I, Scarpelli M, Boccon-Gibod L, Kirkali Z, van PH. Handling and pathology reporting of renal tumor specimens. Eur Urol 2004;45(4):437-443; PMID:15041106; http://dx.doi.org/10.1016/j.eururo.2003.11.026
22. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003; 27(5):612-624; PMID:12717246; http://dx.doi.org/10.1097/00000478-200305000-00005
23. Jones TD, Eble JN, Cheng L. Application of molecular diagnostic techniques to renal epithelial neoplasms. Clin Lab Med 2005; 25(2):279-303; PMID:15848737; http://dx.doi.org/10.1016/j.cll.2005.01.011
24. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC, Press, Lyon. In press.
25. Staehler M, Rohrmann K, Bachmann A, Zaak D, Stief CG, Siebels M. Therapeutic approaches in metastatic renal cell carcinoma. BJU Int 2005;95(8):1153-61; PMID:15877725; http://dx.doi.org/10.1111/j.1464-410X.2005.05537.x
26. Vogl UM, Zehetgruber H, Dominkus M, Hejna M, Zielinski CC, Haitel A, Schmidinger M. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer 2006; 95(6):691-8; PMID:16940978; http://dx.doi. org/10.1038/sj.bjc.6603327
27. Ljungberg B. The role of metastasectomy in renal cell carcinoma in the era of targeted therapy. Curr Urol Rep 2013;14(1):19-25; PMID:23212738; http://dx. doi.org/10.1007/s11934-012-0293-6
28. Stadler WM. Maturing of renal cancer therapeutics. J Clin Oncol 2014;32(8):722-724; PMID:24516015; http://dx.doi.org/10.1200/JCO.2013.54.1748
29. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw 2009;7(6):618-30; PMID:19555584
30. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC; European Association of Urology Guideline Group. EAU Guidelines on Renal Cell Carcinoma: The 2010 Update. Eur Urol 2010;58:398-406; PMID:20633979
31. Escudier B, Kataja V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v137-9; PMID:20555064; http://dx.doi.org/10.1093/annonc/mdq206
32. Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993;11:213-44; PMID:8476560; http://dx. doi.org/10.1146/annurev.iy.11.040193.001241
33. Molenkamp BG, Vuylsteke RJ, van Leeuwen PA, Meijer S, Vos W, Wijnands PG, Scheper RJ, de Gruijl TD. Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells. Am J Pathol 2005;167(5):1301-7; PMID:16251414; http://dx.doi.org/10.1016/S0002-9440(10)61217-5
34. Weinschenk T, Singh H, Mahr A, Fritsche J. Biomarkers for predicting the efficacy of an immunotherapy against cancer, Patent PCT/EP2011/070661, published as WO2012069462. 2012 May 31.
35. Dutoit V, Herold-Mende C, Hilf N, Schoor O, Beckhove P, Bucher J, Dorsch K, Flohr S, Fritsche J, Lewandrowski P, et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 2012;135(Pt 4):1042-54; PMID:22418738; http://dx.doi.org/10.1093/brain/aws042
36. Berinstein NL. Enhancing cancer vaccines with immunomodulators. Vaccine 2007;25 Suppl 2:B72-88; PMID:17916464; http://dx.doi.org/10.1016/j.vaccine.2007.06.043
37. Hege KM, Jooss K, Pardoll D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol 2006;25(5-6):321-352; PMID:17169779; http://dx.doi.org/10.1080/08830180600992498
38. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for cas-tration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22; PMID:20818862; http://dx.doi. org/10.1056/NEJMoa1001294
39. Biskamp M, Jaeger E, Karbach J et al. Phase I study of intensive course immunization with NY-ESO-1 peptides in HLA-A2C patients with NY-ESO-1C cancer. ASCO Conference 2003. Proc Am Soc Clin Oncol (ASCO 2003) 22[706].2003
40. Gaudernack G, Buanes T, Meo M et al. Clinical trials of a peptide based vaccine targeting telomerase. Proc Am Soc Clin Oncol (ASCO 2003) 22[666].2003.
41. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007;18(2):226-32; PMID:17116643; http://dx.doi.org/10.1093/annonc/ mdl158
42. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942-9; PMID:15322536; http://dx.doi. org/10.1038/nm1093
43. Chen W, Cai MY, Wei DP, Wang X. Pivotal molecules of MHC I pathway in human primary hepatocellular carcinoma. World J Gastroenterol 2005;11(21):3297-9; PMID:15929187
44. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004;200 (6):771-82; PMID:15381730; http://dx.doi.org/10.1084/jem.20041130
45. Berd D, Maguire HC, Jr., Mastrangelo MJ. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res 1984;44 (11):5439-5443; PMID:6488195
46. Faries MB, Hsueh EC, Gupta RK et al. Immunomodulation of responses to active immunization with a polyvalent immunotherapeutic: cyclophosphamide, H2 blockade, IL-2/IFNa and GM-CSF. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings Vol 23, No.16S, Part I of II (June 1 Supplement)[2564].2005.
47. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B, et al. Metronomic cyclophosphamide regimen selectively depletes CD4CCD25C regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56(5):641-8; PMID:16960692; http://dx.doi. org/10.1007/s00262-006-0225-8
48. Greten TF, Ormandy LA, Fikuart A, H€ochst B, Henschen S, H€orning M, Manns MP, Korangy F. Lowdose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4C T-cell responses in patients with advanced HCC. J Immunother 2010;33(2):211-8; PMID:20139774; http://dx.doi. org/10.1097/CJI.0b013e3181bb499f
49. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008;14(5):1455-63; PMID:18316569; http://dx.doi.org/10.1158/1078-0432.CCR-07-0371
50. Livingston PO, Cunningham-Rundles S, Marfleet G, Gnecco C, Wong GY, Schiffman G, Enker WE, Hoffman MK, et al. Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma. J Biol Response Mod 1987;6(4):392-403; PMID:2957470
51. Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988;48(20):5883-93; PMID:3262416
52. Salem ML, Kadima AN, El-Naggar SA, Rubinstein MP, Chen Y, Gillanders WE, Cole DJ. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8C T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother 2007;30(1):40-53; PMID:17198082; http://dx.doi.org/10.1097/01.cji.0000211311.28739.e3
53. Radojcic V, Bezak KB, Skarica M, Pletneva MA, Yoshimura K, Schulick RD, Luznik L. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother 2010;59(1):137-48; PMID:19590872; http://dx.doi.org/10.1007/s00262-009-0734-3
54. Nakahara T, Uchi H, Lesokhin AM, Avogadri F, Rizzuto GA, Hirschhorn-Cymerman D, Panageas KS, Merghoub T, Wolchok JD, Houghton AN. Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood 2010;115(22):4384-92; PMID:20154220; http://dx.doi.org/10.1182/blood-2009-11-251231
55. Liu Y, Laszlo C, Liu Y, Liu W, Chen X, Evans SC, Wu S. Regulation of G(1) arrest and apoptosis in hypoxia by PERK and GCN2-mediated eIF2alpha phosphorylation. Neoplasia 2010;12(1):61-68; PMID:20072654
56. Ibe S, Qin Z, Schuler T, Preiss S, Blankenstein T. Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med 2001;194(11):1549-59; PMID:11733570; http://dx.doi.org/10.1084/jem.194.11.1549
57. Pelaez B, Campillo JA, Lopez-Asenjo JA, Subiza JL. Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism. J Immunol 2001;166 (11):6608-15; PMID:11359814; http://dx.doi.org/10.4049/jimmunol.166.11.6608
58. Fuentes D, Avellanet J, Garcia A, Iglesias N, Gabri MR, Alonso DF, Vazquez AM, Perez R, Montero E. Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model. Breast Cancer Res Treat 2010;120(2):379-389; PMID:19377876; http://dx.doi.org/10.1007/s10549-009-0399-9
59. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012;18:1254-61; PMID:22842478; http://dx. doi.org/10.1038/nm.2883
60. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-16; PMID:10655437; http://dx.doi.org/10.1093/jnci/92.3.205
61. FDA. Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines. 2011.
62. Hoos A. Evolution of end points for cancer immunotherapy trials. Ann Oncol 2012;23 Suppl 8:viii47-52; PMID:22918928; http://dx.doi.org/10.1093/annonc/mds263
63. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW. Integrated data from 2 randomized, double-blind, placebocontrolled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115(16):3670-79; PMID:19536890; http://dx.doi.org/10.1002/cncr.24429
64. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24(19):3089-94; PMID:16809734; http://dx.doi.org/10.1200/JCO.2005.04.5252
65. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-smallcell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15(1):59-68; PMID:24331154; http://dx.doi.org/10.1016/S1470-2045(13)70510-2
66. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSAtargeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28(7):1099-105; PMID:20100959; http://dx.doi.org/10.1200/ JCO.2009.25.0597
67. Ullenhag GJ, Frodin JE, Jeddi-Tehrani M, Striga Eriksson E, Samanci A, Choudhury A, Nilsson B, Rossmann ED, Mosolits S, et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin Cancer Res 2004;10 (10):3273-81; PMID:15161680; http://dx.doi.org/10.1158/1078-0432.CCR-03-0706
68. Staff C, Magnusson CG, Hojjat-Farsangi M, Mosolits S, Liljefors M, Frödin JE, Wahrén B, Mellstedt H, Ullenhag GJ. Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein. J Clin Immunol 2012;32:855-65; PMID:22382876
69. Mosolits S, Ullenhag G, Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol 2005;16(6):847-62; PMID:15829493; http:// dx.doi.org/10.1093/annonc/mdi192
70. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004;64(14):4973-79; PMID:15256471; http://dx.doi.org/10.1158/ 0008-5472.CAN-03-3505
71. Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Döorfel D, Schmidt SM, Häntschel M, Brugger W, Schröder S, Horger MS, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006;66(11):5910-18; PMID:16740731; http://dx.doi.org/10.1158/0008-5472.CAN-05-3905
72. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312-18; PMID:19451442; http://dx. doi.org/10.1200/JCO.2008.19.5511
73. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16-24; PMID:16330672; http://dx.doi.org/10.1200/JCO.2005.02.2574
74. Hodge JW, Chakraborty M, Kudo-Saito C, Garnett CT, Schlom J. Multiple costimulatory modalities enhance CTL avidity. J Immunol 2005;174(10):5994-6004; PMID:15879092; http://dx.doi.org/10.4049/jimmunol.174.10.5994
75. Karyampudi L, Lamichhane P, Scheid AD, Kalli KR, Shreeder B, Krempski JW, Behrens MD, Knutson KL. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res 2014; 74:2974-85; PMID:24728077; http://dx.doi.org/10.1158/0008-5472.CAN-13-2564
76. Fu J, Malm IJ, Kadayakkara DK, Levitsky H, Pardoll D, Kim YJ. Preclinical evidence that PD-1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res 2014;74:4042-52; PMID:24812273; http://dx.doi. org/10.1158/0008-5472
77. Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Samara R, Rotem-Yehudar R, Cook L, Khleif SN. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol 2011;41 (10):2977-86; PMID:21710477; http://dx.doi.org/10.1002/eji.201141639
78. Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012;13(5):501-8; PMID:22326924; http://dx.doi.org/10.1016/S1470-2045(12)70006-2
79. Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013;36(7):382-9; PMID:23924790; http://dx. doi.org/10.1097/CJI.0b013e31829fb7a2
80. Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009;15(19):6267-76; PMID:19789309; http://dx.doi.org/10.1158/1078-0432.CCR-09-1254
81. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
82. Cho D, Sosman JA, Sznol M et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 31[(15-suppl), Abstract 4505]. 2013.